FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
FiercePharma

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
PharmaTimes

GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard ...
The Financial

Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
Medscape

CHMP Backs Relvar Ellipta for Asthma, COPD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for fluticasone furoate/vilanterol (FF/VI) (Relvar Ellipta, ...
FierceBiotech

GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe

Relvar(TM) and Breo(TM) Proposed as Brand Names for FF/VI in EU and US; New Dry Powder Inhaler Proposed to be Named Ellipta(TM) LONDON and SOUTH SAN FRANCISCO, Calif., Jul 13, 2012 -- GlaxoSmithKline ...
PharmaTimes

EU expands scope of GSK/Innoviva’s asthma inhaler

The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach. The European Commission ...
Yahoo Finance

RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...